Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04001777 | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | PHASE1 | ACTIVE NOT_RECRUITING | 80 | — | — | Jul 4, 2019 | Jun 1, 2026 | Oct 1, 2025 | 4 | China, China +2 |
| Name | Type | Description |
|---|---|---|
| APG-1252 | DRUG | Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days. |
| Osimertinib Mesylate Tablets | DRUG | Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression |